WASHINGTON, April 20 /PRNewswire-USNewswire/ — AdvaMed Dx, a division of the Advanced Medical Technology Association (AdvaMed) focused on topics affecting the in vitro diagnostics industry, is pleased to welcome Siemens Healthcare Diagnostics as the association's newest member. Donal Quinn, chief executive officer of Siemens Healthcare Diagnostics, has been appointed to the AdvaMed Dx Board of Directors.
"We are delighted to welcome Siemens as the newest member of AdvaMed Dx," said Stephen J. Ubl, president and chief executive officer of AdvaMed. "This is a critical time for the industry, with health reform behind us and implementation ahead. Now more than ever, there are significant opportunities to promote public policies that will ensure patient access to life-enhancing blood tests and continued innovation in this critical area of medical diagnosis, monitoring and treatment. Siemens' addition to AdvaMed Dx and its board will aid us in that effort," said Ubl.
"Siemens is pleased to work with AdvaMed Dx to help healthcare providers around the world improve the quality, efficiency and accessibility of healthcare," said Quinn. "We believe AdvaMed Dx is strongly positioned to engage on the important issues impacting the clinical diagnostics industry today."
AdvaMed Dx now represents more than 50 of the industry's leading in vitro diagnostics companies. Some of the issues of particular importance to AdvaMed Dx include the establishment of a modernized risk-based approach to the regulation of in vitro diagnostics and reforming the Medicare payment system for clinical laboratory diagnostic tests to fully recognize the value of new tests, including the new generation of molecular diagnostic tests.
AdvaMed Dx member companies produce advanced, in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMed Dx is the only multi-faceted, policy organization that deals exclusively with issues facing in vitro diagnostic companies both domestically in the United States and abroad. For more information, visit www.advamed.org .
Wanda Moebius, Vice President, Policy Communications, AdvaMed, +1-202-434-7240